Edesa BiotechEDSA +5.58%26 Quick Ratio is 4.76 as of Mar. 2026, which is 38% below its 10-year median of 7.70. GuruFocus rates EDSA with a GF Score™ of 26/100. The stock has 2 warning signs investors should review. Among 1,417 Biotechnology companies, Edesa Biotech ranks better than 57.8% on this metric.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Edesa Biotech's quick ratio for the quarter that ended in Mar. 2026 was 4.76.
Edesa Biotech has a quick ratio of 4.76. It generally indicates good short-term financial strength.
The historical rank and industry rank for Edesa Biotech's Quick Ratio or its related term are showing as below:
EDSA'
s Quick Ratio Range Over the Past 10 Years
Min: 0.91 Med: 7.7 Max: 27.46
Current: 4.76
During the past 13 years, Edesa Biotech's highest Quick Ratio was 27.46. The lowest was 0.91. And the median was 7.70.
EDSA's Quick Ratio is ranked better than 57.8% of 1417
companies
in the Biotechnology industry
Industry Median: 3.6
vs EDSA: 4.76
Edesa Biotech (NAS:EDSA) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Edesa Biotech Quick Ratio Related Terms
Edesa Biotech Quick Ratio Historical Data
* Premium members only.
The historical data trend for Edesa Biotech's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Edesa Biotech's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Edesa Biotech Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Edesa Biotech's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Edesa Biotech's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Edesa Biotech's Quick Ratio for the fiscal year that ended in Sep. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Edesa Biotech (EDSA) has a Quick Ratio of 4.76 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Edesa Biotech and its competitors. This is 38% below median its historical median of 7.70. Over the past decade, Edesa Biotech's Quick Ratio has ranged from 0.91 to 27.46. According to the industry distribution chart, Edesa Biotech ranks #598 out of 1417 companies in the Biotechnology industry, placing it in the top 42.2%.
Is Edesa Biotech's Quick Ratio too high?
Edesa Biotech's current Quick Ratio of 4.76 is 38% below median its 10-year median of 7.70. Over the past 10 years, this metric has ranged from a low of 0.91 to a high of 27.46. The Biotechnology industry median Quick Ratio is 3.60. Edesa Biotech's value of 4.76 is 32.2% above this industry median. Based on the distribution chart, Edesa Biotech ranks #598 out of 1417 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Edesa Biotech has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Edesa Biotech's Quick Ratio compare to PMVP and IMA?
According to the Biotechnology industry distribution chart, Edesa Biotech ranks #598 out of 1417 companies for Quick Ratio. This puts Edesa Biotech in the upper half of its industry. The industry median Quick Ratio is 3.60. Edesa Biotech's value of 4.76 is 32.2% above this benchmark. Historically, Edesa Biotech's own Quick Ratio has ranged from 0.91 to 27.46 over the past decade. While the company's 10-year median is 7.70 vs. the industry median of 3.60, Edesa Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,417 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Edesa Biotech's current Quick Ratio of 4.76 is 32.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Edesa Biotech and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Edesa Biotech's current Quick Ratio is 4.76, which is 38% below median its own 10-year median of 7.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Edesa Biotech stock overvalued right now?
Edesa Biotech (EDSA) has a current Quick Ratio of 4.76. The current Quick Ratio is 4.76, which is 38% below median its 10-year median of 7.70 and 32.2% above the Biotechnology industry median of 3.60. Edesa Biotech's overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Edesa Biotech (EDSA), the current Quick Ratio is 4.76 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.
26GF Score
Get the complete analysis for EDSA
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EDSA has been successfully added to your 
